湖南發展(000722.SZ):擬參與認購吉林化纖非公開發行A股股票
格隆匯6月22日丨湖南發展(000722.SZ)公佈,吉林化纖擬向不超過35名特定對象發行A股股票,股票數量不超過3億股(含本數),募集資金總額不超過12億。其中:9億元用於1.2萬噸碳纖維復材項目,3億元用於償還銀行借款。吉林化纖此次非公開發行股票事項已獲得中國證監會證監許可[2022]689號批文核准。
為進一步優化公司資產結構,提升資金使用效率,根據公司發展戰略規劃,公司擬在董事會授權金額範圍內以自有資金參與認購吉林化纖非公開發行股票(若公司獲配吉林化纖非公開發行股票,最終認購金額以實際獲配為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.